An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Ireland Limits Planned Trade Ban on Israeli Settlements to Goods Only
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand
Fed Near Neutral Signals Caution Ahead, Shifting Focus to Fixed Income in 2026
Australia’s Labour Market Weakens as November Employment Drops Sharply
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Indonesia–U.S. Tariff Talks Near Completion as Both Sides Push for Year-End Deal 



